evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract
19021,GENE_BACKGROUND,,"The PDCD1LG2 gene encodes the ""programmed cell death 1 ligand 2"" (PD-L2) protein. PD-L2 is highly similar to PD-L1, a protein whose overexpression by tumor cells and antigen presenting cells (APC) leads to negative regulation of T-cell receptor (TCR) signaling and subsequent tumor immune evasion (PMID: 15599732, 22437870). PD-L2 binding affinity for PD-1 is higher than PD-L1, although the biological consequences of this are unknown (PMID: 12893276). PD-L2 is also expressed in activated T-helper cells type 2 (Th2), inhibiting its function and regulating IFN-Î³ production (PMID: 21752471). Impaired tumor growth has been observed in several in vitro and in vivo cancer models upon dual PD-L1/PD-L2 inhibition, but the specific additive role for the latter remains elusive (PMID: 22611421). PDCD1LG2 overexpression or amplification has been reported in renal, cervical and breast cancers, among others, and in some cases predicts poor prognosis (PMID: 26464193, 26913631, 26424759, 26752545, 26317899, 24270737, 15837746). PDCD1LG2 is a putative target for cancer immunotherapy (PMID: 22658128, 22611421).",,2017-03-28,,80380,PDCD1LG2,programmed cell death 1 ligand 2,False,ENST00000397747,NM_025239.3,CD273,bA574F11.2,PD-L2,PDCD1L2,B7DC,Btdc,PDL2,False,22611421,Programmed death ligand 2 in cancer-induced immune suppression.,Clinical &amp; developmental immunology,2012,2012,,656340,Rozali EN et al,doi: 10.1155/2012/656340,,Rozali EN et al. Clinical &amp; developmental immunology. 2012;2012()656340.,,26752545,Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.,The American journal of surgical pathology,2018-04-01T20:16:00,40,4,443-53,Xu J et al,doi: 10.1097/PAS.0000000000000590,,0001-04-01,,22437870,The blockade of immune checkpoints in cancer immunotherapy.,Nature reviews. Cancer,2018-03-22T20:12:00,12,4,252-64,Pardoll DM,doi: 10.1038/nrc3239,,0001-03-22,,26424759,The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.,The oncologist,2018-11-01T20:15:00,20,11,1253-60,Shin SJ et al,doi: 10.1634/theoncologist.2015-0151,,0001-11-01,,26317899,"Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.",Oncotarget,2018-09-22T20:15:00,6,28,26483-93,Barrett MT et al,doi: 10.18632/oncotarget.4494,,0001-09-22,,21752471,PD-L2 is expressed on activated human T cells and regulates their function.,Molecular immunology,2018-09-01T20:11:00,48,15-16,2214-9,Messal N et al,doi: 10.1016/j.molimm.2011.06.436,,2017-11-16,,15599732,Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.,"Cancer immunology, immunotherapy : CII",2018-04-01T20:05:00,54,4,307-14,Blank C et al,,,0001-04-01,,24270737,"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.",Leukemia,2018-06-01T20:14:00,28,6,1280-8,Yang H et al,doi: 10.1038/leu.2013.355,,0001-06-01,,26464193,Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in  Renal Cell Carcinoma: Association with Oncogenic Proteins  Status.,Annals of surgical oncology,2018-02-01T20:16:00,23,2,694-702,Shin SJ et al,,,2018-02-01T07:02:00,,26913631,Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.,JAMA oncology,2018-04-01T20:16:00,2,4,518-22,Howitt BE et al,doi: 10.1001/jamaoncol.2015.6326,,0001-04-01,,15837746,Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.,Clinical cancer research : an official journal of the American Association for Cancer Research,2018-04-15T20:05:00,11,8,2947-53,Ohigashi Y et al,,,0001-04-15,,12893276,Differential binding properties of B7-H1 and B7-DC to programmed death-1.,Biochemical and biophysical research communications,2018-08-01T20:03:00,307,3,672-7,Youngnak P et al,,,0001-08-01,,22658128,Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.,The New England journal of medicine,2018-06-28T20:12:00,366,26,2455-65,Brahmer JR et al,doi: 10.1056/NEJMoa1200694,,0001-06-28,
19020,GENE_SUMMARY,,"PDCD1LG2, a ligand of T-cell receptors involved in immune suppression, is overexpressed in various tumors.",,2017-03-28,,80380,PDCD1LG2,programmed cell death 1 ligand 2,False,ENST00000397747,NM_025239.3,CD273,bA574F11.2,PD-L2,PDCD1L2,B7DC,Btdc,PDL2,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
